Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Lance B's : Its A Beautiful Thing -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (3512)	1/29/2000 11:36:00 PM
From: LANCE B	Read Replies (3) \| Respond to of 4792

BCAM- DOES ANYBODY REMEMBER HAVING A SHOT TO BUY IMDS AT A DIME... n January 5, 2000, LungCheck Health, Inc. ("LungCheck"), a wholly owned subsidiary of BCAM International, Inc. announced a cooperative educational agreement with Pavonia Medical Associates of New Jersey whereby the company will provide consumer and physician educational funds to highlight awareness of pulmonary disease and the importance of early detection and prevention of lung disease. Pavonia Medical Associates is one of the leading multi-specialty clinics in the New York/New Jersey area with over 70 physicians in 3 locations (Jersey City, Secaucus and North Bergen). Pavonia Medical also has one of the most respected pulmonary medicine practices in New Jersey and draws patients from as far as Connecticut due to their state-of-the-art diagnostic capabilities and advanced smoking cessation clinic. "LungCheck has been a part of our disease management and smoking cessation strategies for the past several years," said Dr. Victor Marchione, F.C.C.P., Medical Director of Pavonia Medical Associates. "With LungCheck's sputum evaluation, we can assess the level of pulmonary damage in any given patient quickly and non-invasively. LungCheck data provides an objective foundation which guides the clinician before ordering more costly diagnostic studies. LungCheck can detect the earliest cellular changes in the lung and, thereby, lead to much earlier treatment of disease. The ease and convenience in using the take-home, postage paid, single-canister sputum collection system make patient acceptance and compliance surprisingly high. Pavonia clinicians routinely use the LungCheck Cytogram(TM) Report to encourage smoking cessation efforts and periodically assess these high-risk patients for lung carcinoma. Indeed, LungCheck has made a significant difference in the quality of patient care in our clinics by providing a reliable, cost-effective screening tool as part of the initial patient assessment for lung disease." Said Mr. Michael Strauss, CEO and Chairman of LungCheck Health, "This agreement heralds a new level of cooperation between companies specializing in medical innovation, such as ours, and mainstream clinical practice. For the first time, we are not touting our own ability to save medical costs and save patient lives, a well-respected practice has stepped up to the plate and will demonstrate the positive impact we have made and will carry that message in formal physician training and awareness campaigns to other practices." As part of the agreement, Pavonia has committed to featuring LungCheck in advertisements for their smoking cessation clinics and will speak on behalf of the product and demonstrate cost savings models and patient management protocols that they have developed to other physicians at regularly scheduled presentations. Strauss continued, "Pavonia approached us and explained that in the last two years our program had detected cancerous or pre-cancerous lesions in several patients that would have otherwise gone undetected -- we helped to save lives. We're graphically demonstrating the need to quit smoking, we are monitoring people at high risk of pulmonary disease in hazardous occupations and we are making a difference. We always knew that the refinements made to our test over the last 10 years to distinguish it from routine sputum cytology would make LungCheck one of the most inexpensive and accurate tests available -- we've just been fighting to prove the cost benefit to insurance companies and break in to traditional diagnostic protocols. Pavonia Medical Associates, independently, is making the case for us with their name and the caliber of physicians associated with their practice. Our Company will remain an active supporter of lung disease awareness through our programs with these types of physicians." LungCheck is a pathology services company specializing in early lung disease screening and the assessment of lung health through the utilization of its proprietary quantitative sputum cytology test called LungCheck(R). The Company currently distributes its test to large medical clinics where it has been successfully used as a biofeedback mechanism to aid in smoking cessation tool and as monitoring tool for patients who have a family history of pulmonary disease or are recovering from cancer. LungCheck is also used to monitor employees who work in environments where they may be exposed to pulmonary irritants. The Company also distributes its LungCheck(R) Sputum Cytology Test through partnerships with leading providers of testing services to Fortune 500 Companies as part of corporate wellness and/or screening programs in addition to its recently announced plans to promote awareness of the test via the Internet through partnerships with large, regional medical clinics and research centers nationwide. The LungCheck(R) Sputum Cytology Test is the only cost-effective, non-invasive screening device for lung cancer and other pulmonary diseases that provides both early detection and patient monitoring capabilities. Conventional Chest X-Ray and bronchoscopy are routinely used to diagnose and localize lung cancer, but several studies suggest that these techniques are significantly less sensitive than sputum cytology in detecting lung cancer in its earliest stages. Like cervical cancer, if detected early (prior to detecting cancer cells in sputum; i.e. severe dysplasia), lung cancer can be treated successfully in more than 50% of the cases according to the National Cancer Institute (NCI). In 1998, lung cancer (not including other forms of lung disease) was responsible for approximately 160,000 deaths, with 170,000 new cases diagnosed in the United States. Based on the long-term success of the Pap Smear for early detection of cervical cancer, Management believes that LungCheck?, a tool that can be viewed as a 'Pap Smear for the lungs, is an equally valuable tool to be used for the early detection and monitoring of pulmonary disease. The Company conservatively estimates that the United States market for the LungCheck(R) Test is in excess of $1 billion. The Company's common stock appears on the OTC Bulletin Board. The forward-looking statements included in this news release are based on management's current expectations. In light of the assumption and uncertainties inherent in forward looking information, the inclusion of such information should not be regarded as a representation by the Company or any other person that the plans of the Company will be realized or that positive trends in financial results will occur. SOURCE BCAM International, Inc. (C) 2000 PR Newswire. All rights reserved. prnewswire.com -0- CONTACT: Michael Strauss of BCAM International, Inc., 516-752-3550